Skip to Content

Abciximab Disease Interactions

There is 1 disease interaction with abciximab:


Gpiib/Iiia Platelet Inhibitors (Includes Abciximab) ↔ Bleeding Risks

Severe Potential Hazard, High plausibility

Applies to: Thrombocytopenia, Coagulation Defect, Hypertension, Bleeding, Brain/Intracranial Tumor, Thrombocytopathy, Cerebral Vascular Disorder

The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.


  1. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol 78 (1996): 1161
  2. Kleiman NS "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol 80 (1997): b29-33
  3. The IMPACT-II Investigators "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet 349 (1997): 1422-8
  4. Adgey AA "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J 135 (1998): s43-55
  5. "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.
  6. "Product Information. Aggrastat (tirofiban)." Merck & Co, Inc, West Point, PA.
  7. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol 74 (1994): 1166-70
  8. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987): 703-13
  9. The RESTORE Investigators "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation 96 (1997): 1445-53
View all 9 references

abciximab drug Interactions

There are 208 drug interactions with abciximab

abciximab alcohol/food Interactions

There is 1 alcohol/food interaction with abciximab

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.